Skip to main content
. Author manuscript; available in PMC: 2024 Oct 17.
Published in final edited form as: Semin Respir Crit Care Med. 2024 Mar 14;45(3):329–341. doi: 10.1055/s-0044-1782218

Fig. 2.

Fig. 2

Treatment medication choices. Immunosuppressants are considered first-line therapy in RA-ILD, with mycophenolate mofetil, azathioprine, and rituximab consistently shown to improve lung function in RA-ILD in observational studies. Evidence also supports abatacept as a treatment choice, particularly for patients with high articular burden. HRCT, high-resolution computed tomography; ILD, interstitial lung disease; PFT, pulmonary function testing.